ArticleAlzheimer's research & therapy2025
KLOTHO-VS heterozygosity, α-klotho protein levels and cognitive performance in Alzheimer's disease.
Article in Alzheimer's research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Elevated plasma klotho levels attenuate Alzheimer's disease pathologies and cognitive decline in APOE ε4 carriers.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- The latest research progress of ligustilide in the prevention and treatment of central nervous system disorders.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundKLOTHO-VS (KL-VS) heterozygosity, a variant of the KLOTHO gene, and its encoded protein, α-Klotho, are associated with brain health and show neuroprotective potential against Alzheimer's disease (AD). We aimed to assess whether KL-VS heterozygosity, cerebrospinal fluid (CSF) and serum soluble α-Klotho (sαKl) levels, would be associated with a lower likelihood of AD and better performance on memory and other cognitive domains in individuals with AD dementia, amnestic mild cognitive impairment (aMCI) due to AD, and cognitively unimpaired controls.
methodsIn this cross-sectional study, we analyzed two partially overlapping subsamples derived from 296 participants from the Czech Brain Aging Study. The first subsample included 196 participants with KL-VS haplotype data: 71 with AD dementia, 84 with aMCI due to AD, and 41 cognitively unimpaired controls. The second subsample included 147 participants with CSF and/or serum sαKl measurements, including 58 with AD dementia, 59 with aMCI due to AD, and 30 cognitively unimpaired controls. Diagnoses of aMCI and AD dementia were confirmed by positive CSF biomarkers and/or amyloid PET imaging. Logistic regression assessed how KL-VS heterozygosity influenced the odds of aMCI or dementia due to AD. Linear regression investigated associations between cognitive performance and either KL-VS heterozygosity or CSF/serum sαKl levels. Analysis of variance and analysis of covariance with post-hoc tests were used to compare sαKl levels across study groups.
resultsKL-VS heterozygosity carriers showed a consistent trend towards lower odds of being classified with aMCI and dementia due to AD, with similar patterns in both Apolipoprotein E ε4 (APOE ε4) allele carriers and non-carriers, although none of the associations reached statistical significance despite moderate (rather than small) effect sizes. Among individuals with aMCI due to AD, KL-VS heterozygotes displayed better memory performance (β = 0.61, p = .008), particularly those who also carried the APOE ε4 allele (β = 0.64, p = .042). Results with other cognitive domains were non-significant. No significant differences in sαKl levels were found between study groups, and soluble α-Klotho levels did not associate with memory performance.
conclusionsKL-VS heterozygosity may be linked to lower likelihood of classification as aMCI or dementia due to AD, and its association with memory might be specific to the aMCI stage of AD and modulated by APOE ε4 status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.